- India
- /
- Life Sciences
- /
- NSEI:INNOVACAP
Innova Captab Second Quarter 2025 Earnings: EPS: ₹6.12 (vs ₹4.77 in 2Q 2024)
Innova Captab (NSE:INNOVACAP) Second Quarter 2025 Results
Key Financial Results
- Revenue: ₹3.20b (up 13% from 2Q 2024).
- Net income: ₹350.0m (up 53% from 2Q 2024).
- Profit margin: 11% (up from 8.1% in 2Q 2024). The increase in margin was driven by higher revenue.
- EPS: ₹6.12 (up from ₹4.77 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Innova Captab Earnings Insights
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
Performance of the Indian Life Sciences industry.
The company's shares are up 21% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for Innova Captab that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:INNOVACAP
Innova Captab
An integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally.
Flawless balance sheet with high growth potential.